Drug repurposing in the context of common bacterial patho-gens:
insights from an in vitro study

J 2022

Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study

DONADU, Matthew Gavino; Donadu ZANETTI; Basem BATTAH; Helal F. HETTA; Danica MATUSOVITS et al.

Základní údaje

Originální název

Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study

Autoři

Vydání

Acta Biologica Szegediensis, University of Szeged, 2022, 1588-385X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10606 Microbiology

Stát vydavatele

Maďarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/22:00129848

Organizační jednotka

Přírodovědecká fakulta

DOI

https://doi.org/10.14232/abs.2022.2.140-149

EID Scopus

2-s2.0-85161404677

Klíčová slova anglicky

antibiotic resistance; ciprofloxacin; ceftriaxone; drug repurposing; drug repositioning; gentamicin; non-antibiotic compounds; multidrug resistance

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 7. 2023 09:21, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

The clinical problem of multidrug resistance (MDR) in bacteria is due to the lack of novel antibiotics in development and the dwindling pipeline of drugs receiving market authorization. Repurposing of non-antibiotic pharmacological agents may be an attractive pathway to provide new antimicrobial drugs. The aim of the present study was to ascertain the antibacterial and adjuvant properties of a wide range of pharmaceuticals against antibiotic-susceptible and drug-resistant bacteria. Sixty-five (n = 65) pharmacological agents were included in our experiments. For Gram-positive bacteria, Staphylococcus aureus ATCC 43300 (methicillin-resistant), S. epidermidis ATCC 12228, Streptococcus pyogenes ATCC 12384 and Enterococcus faecalis ATCC 29212 were used, while for Gram-negative bacteria, Enterobacter cloacae ATCC 13047 (extended-spectrum β-lactamase-positive), Klebsiella pneumoniae ATCC 49619, Serratia marcescens ATCC 29632 and Pseudomonas aeruginosa ATCC 27853 were included as representative strains. The minimum inhibitory concentrations (MICs) of the tested compounds were determined using the standard broth microdilution method, while a MIC reduction assay was included to ascertain the effect of the tested compounds on the MICs of standard antibiotics (ceftriaxone, ciprofloxacin and gentamicin). Seventeen and twelve drug molecules tested showed measurable antibacterial activities (MIC: 32-512 µg/mL) against Gram-positive and Gram-negative bacteria, respectively. Several compounds decreased the MICs of ciprofloxacin and gentamicin. Although there are increasing number of studies in this field, there are still significant gaps in the evidence to the potential use of non-antibiotic drugs in antimicrobial drug repurposing.

Citovat

DONADU, Matthew Gavino; Donadu ZANETTI; Basem BATTAH; Helal F. HETTA; Danica MATUSOVITS; Krisztina KÁRPÁTI; Virág FINTA; Berta CSONTOS; Anna KUKLIS; Fruzsina SZIKORA; Adrienn CSEGÉNY; Lea SZALMA; Eszter MAJOR; Ivan KUSHKEVYCH a Márió GAJDÁCS. Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study. Acta Biologica Szegediensis. University of Szeged, 2022, roč. 66, č. 2, s. 140-149. ISSN 1588-385X. Dostupné z: https://doi.org/10.14232/abs.2022.2.140-149.

@article{2287638,
   author = {Donadu, Matthew Gavino and Zanetti, Donadu and Battah, Basem and Hetta, Helal F. and Matusovits, Danica and Kárpáti, Krisztina and Finta, Virág and Csontos, Berta and Kuklis, Anna and Szikora, Fruzsina and Csegény, Adrienn and Szalma, Lea and Major, Eszter and Kushkevych, Ivan and Gajdács, Márió},
   article_number = {2},
   doi = {https://doi.org/10.14232/abs.2022.2.140-149},
   keywords = {antibiotic resistance; ciprofloxacin; ceftriaxone; drug repurposing; drug repositioning; gentamicin; non-antibiotic compounds; multidrug resistance},
   language = {eng},
   issn = {1588-385X},
   journal = {Acta Biologica Szegediensis},
   title = {Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study},
   url = {https://doi.org/10.14232/abs.2022.2.140-149},
   volume = {66},
   year = {2022}
}

TY  - JOUR
ID  - 2287638
AU  - Donadu, Matthew Gavino - Zanetti, Donadu - Battah, Basem - Hetta, Helal F. - Matusovits, Danica - Kárpáti, Krisztina - Finta, Virág - Csontos, Berta - Kuklis, Anna - Szikora, Fruzsina - Csegény, Adrienn - Szalma, Lea - Major, Eszter - Kushkevych, Ivan - Gajdács, Márió
PY  - 2022
TI  - Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study
JF  - Acta Biologica Szegediensis
VL  - 66
IS  - 2
SP  - 140-149
EP  - 140-149
PB  - University of Szeged
SN  - 1588385X
KW  - antibiotic resistance
KW  - ciprofloxacin
KW  - ceftriaxone
KW  - drug repurposing
KW  - drug repositioning
KW  - gentamicin
KW  - non-antibiotic compounds
KW  - multidrug resistance
UR  - https://doi.org/10.14232/abs.2022.2.140-149
N2  - The clinical problem of multidrug resistance (MDR) in bacteria is due to the lack of novel antibiotics in development and the dwindling pipeline of drugs receiving market authorization. Repurposing of non-antibiotic pharmacological agents may be an attractive pathway to provide new antimicrobial drugs. The aim of the present study was to ascertain the antibacterial and adjuvant properties of a wide range of pharmaceuticals against antibiotic-susceptible and drug-resistant bacteria. Sixty-five (n = 65) pharmacological agents were included in our experiments. For Gram-positive bacteria, Staphylococcus aureus ATCC 43300 (methicillin-resistant), S. epidermidis ATCC 12228, Streptococcus pyogenes ATCC 12384 and Enterococcus faecalis ATCC 29212 were used, while for Gram-negative bacteria, Enterobacter cloacae ATCC 13047 (extended-spectrum β-lactamase-positive), Klebsiella pneumoniae ATCC 49619, Serratia marcescens ATCC 29632 and Pseudomonas aeruginosa ATCC 27853 were included as representative strains. The minimum inhibitory concentrations (MICs) of the tested compounds were determined using the standard broth microdilution method, while a MIC reduction assay was included to ascertain the effect of the tested compounds on the MICs of standard antibiotics (ceftriaxone, ciprofloxacin and gentamicin). Seventeen and twelve drug molecules tested showed measurable antibacterial activities (MIC: 32-512 µg/mL) against Gram-positive and Gram-negative bacteria, respectively. Several compounds decreased the MICs of ciprofloxacin and gentamicin. Although there are increasing number of studies in this field, there are still significant gaps in the evidence to the potential use of non-antibiotic drugs in antimicrobial drug repurposing.
ER  -

DONADU, Matthew Gavino; Donadu ZANETTI; Basem BATTAH; Helal F. HETTA; Danica MATUSOVITS; Krisztina KÁRPÁTI; Virág FINTA; Berta CSONTOS; Anna KUKLIS; Fruzsina SZIKORA; Adrienn CSEGÉNY; Lea SZALMA; Eszter MAJOR; Ivan KUSHKEVYCH a Márió GAJDÁCS. Drug repurposing in the context of common bacterial patho-gens: insights from an in vitro study. \textit{Acta Biologica Szegediensis}. University of Szeged, 2022, roč.~66, č.~2, s.~140-149. ISSN~1588-385X. Dostupné z: https://doi.org/10.14232/abs.2022.2.140-149.

Přehled o publikaci